Brief: Mustang Bio Expands Into Autoimmune Diseases With CAR T-Cell Therapy Platform
28/03/2024 13:59
March 28 (Reuters) - Mustang Bio:
* MUSTANG BIO ANNOUNCES VISION FOR CAR T-CELL THERAPY
PLATFORM
EXPANSION INTO AUTOIMMUNE DISEASES
* MUSTANG BIO: PLANNING FOR PROOF-OF CONCEPT PHASE 1 TRIAL
EVALUATING MB-106 CD20-TARGETED CAR T-CELL THERAPY IN AUTOIMMUNE
DISEASES UNDERWAY
* MUSTANG BIO: PHASE 1 TRIAL EVALUATING MB-106 CD20-TARGETED
CAR
T-CELL THERAPY EXPECTED TO INITIATE IN Q4
* MUSTANG BIO INC - PIVOTAL TRIAL FOR WALDENSTROM
MACROGLOBULINEMIA (WM) IS EXPECTED TO INITIATE IN SECOND HALF OF
2024
Source text for Eikon: ID:nGNX19gG87
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie